NO20064134L - Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav - Google Patents

Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav

Info

Publication number
NO20064134L
NO20064134L NO20064134A NO20064134A NO20064134L NO 20064134 L NO20064134 L NO 20064134L NO 20064134 A NO20064134 A NO 20064134A NO 20064134 A NO20064134 A NO 20064134A NO 20064134 L NO20064134 L NO 20064134L
Authority
NO
Norway
Prior art keywords
bouganin
cytotoxins
modified
methods
cell epitope
Prior art date
Application number
NO20064134A
Other languages
English (en)
Other versions
NO338293B1 (no
Inventor
Francis J Carr
Koen Hellendoorn
Jeannick Cizeau
Glenchristopher Macdonald
Matthew Baker
Joycelyn Entwistle
Denis Georges Bosc
Nicholas Ronald Glover
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20064134L publication Critical patent/NO20064134L/no
Publication of NO338293B1 publication Critical patent/NO338293B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SAMMENDRAG Oppfinnelsen tilveiebringer modifiserte former av bouganinprotein som har biologisk aktivitet og en redusert tilbøyelighet til å aktivere humane T-celler ammenlignet med umodifisert bouganinprotein. Oppfinnelsen tilveiebringer også T- celle epitop-peptider av bouganin og modifiserte T-celle epitop-peptider av bouganin om har en redusert tilbøyelighet til å aktivere humane T-celler sammenlignet med umodifisert T-celle epitoppeptid. Oppfinnelsen tilveiebringer også cytotoksiner som omfatter en ligand som binder til kreftceller bundet til de modifiserte bouganinproteinene. Også gitt er fremgangsmåter for å hemme eller nedbryte mammalske kreftceller ved anvendelse av cytotoksinene ifølge oppfinnelsen og farmasøytiske blandinger for behandling av human kreft.
NO20064134A 2004-03-19 2006-09-13 Modifiserte bouganinproteiner, cytotoksiner samt anvendelse derav, og fremgangsmåte for fremstilling av et farmasøytikum, samt nukleinsyremolekyl og et T-celle epitope peptid NO338293B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55458004P 2004-03-19 2004-03-19
US63057104P 2004-11-26 2004-11-26
PCT/CA2005/000410 WO2005090579A1 (en) 2004-03-19 2005-03-18 Modified bouganin proteins, cytotoxins and methods and uses thereof

Publications (2)

Publication Number Publication Date
NO20064134L true NO20064134L (no) 2006-11-08
NO338293B1 NO338293B1 (no) 2016-08-08

Family

ID=34993709

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064134A NO338293B1 (no) 2004-03-19 2006-09-13 Modifiserte bouganinproteiner, cytotoksiner samt anvendelse derav, og fremgangsmåte for fremstilling av et farmasøytikum, samt nukleinsyremolekyl og et T-celle epitope peptid

Country Status (18)

Country Link
US (4) US7339031B2 (no)
EP (1) EP1737961B1 (no)
JP (1) JP5025460B2 (no)
KR (1) KR101165867B1 (no)
AU (1) AU2005224942B2 (no)
BR (1) BRPI0508670B1 (no)
CA (1) CA2560278C (no)
DK (1) DK1737961T3 (no)
EA (1) EA010803B1 (no)
ES (1) ES2424643T3 (no)
HK (1) HK1102306A1 (no)
IL (1) IL177922A (no)
MX (1) MXPA06010716A (no)
NO (1) NO338293B1 (no)
NZ (1) NZ550339A (no)
PL (1) PL1737961T3 (no)
PT (1) PT1737961E (no)
WO (1) WO2005090579A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033533T2 (en) 2003-04-30 2017-12-28 Universität Zuerich A method of treating cancer using immunotoxin
CA2569788C (en) 2004-06-10 2014-03-18 Viventia Biotech Inc. Tumor specific antibody
KR101385886B1 (ko) 2005-02-03 2014-04-24 안티토페 리미티드 인간 항체들과 단백질들
CN104072611A (zh) * 2005-12-21 2014-10-01 维文蒂阿生物公司 与癌症相关的新抗原
CN101389791A (zh) * 2005-12-23 2009-03-18 维文蒂阿生物技术股份有限公司 融合蛋白文库的产生和筛选方法及其应用
CA2668017A1 (en) * 2006-10-30 2008-05-08 Viventia Biotech Inc. Improved conjugates
EP2423222B2 (en) * 2007-01-30 2020-07-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US8263744B2 (en) 2007-04-19 2012-09-11 Viventia Biotechnologies Inc. Binding proteins that bind to EpCAM linked to an effector molecule
EP2167528B1 (en) 2007-06-21 2018-01-10 Angelica Therapeutics, INC. Modified toxins
CA2700815A1 (en) 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
WO2009110944A1 (en) 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2014127211A1 (en) * 2013-02-15 2014-08-21 Research Development Foundation Deimmunized gelonin molecules and therapies
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
KR20160006697A (ko) * 2013-04-12 2016-01-19 비벤티아 바이오 인코포레이티드 간세포 암종을 검출 및 치료하기 위한 조성물 및 방법
KR102068519B1 (ko) 2013-07-01 2020-01-21 삼성전자주식회사 저장 장치, 그것의 쓰기 방법 및 읽기 방법
WO2015048901A1 (en) 2013-10-02 2015-04-09 Viventia Bio Inc. Anti-epcam antibodies and methods of use
US20160060358A1 (en) * 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
CN108513547A (zh) 2015-03-12 2018-09-07 维文蒂亚生物公司 用于epcam阳性膀胱癌的治疗方法
WO2016187571A2 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Her2 immunotoxins and methods of using the same
CN111405911A (zh) 2017-10-10 2020-07-10 梅迪塞纳医疗股份有限公司 用于治疗中枢神经系统(cns)肿瘤的il-4融合制剂
CA3108797A1 (en) * 2018-08-10 2020-02-13 Sanford Burnham Prebys Medical Discovery Institute Binding molecules to tumor associated macrophages and methods of use
JP7124034B2 (ja) * 2020-11-05 2022-08-23 株式会社天柳 嚥下困難者用食品組成物の製造方法
JP7488928B1 (ja) 2023-03-01 2024-05-22 積水フーラー株式会社 ホットメルト接着剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680295B1 (en) * 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1998055623A1 (en) * 1997-06-06 1998-12-10 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
ATE211394T1 (de) * 1997-06-20 2002-01-15 Tanox Pharma B V Anti-cd40l immunotoxine zur behandlung von krankheiten
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
EP1998266A3 (en) * 2001-02-19 2009-02-11 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2003104803A2 (en) 2002-06-11 2003-12-18 Merck Patent Gmbh Method for mapping and eliminating t-cell epitopes
MXPA04012210A (es) 2002-06-11 2005-02-25 Merck Patent Gmbh Birodina i modificada con inmunogenicidad reducida.
CA2424255A1 (en) * 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
CA2569788C (en) 2004-06-10 2014-03-18 Viventia Biotech Inc. Tumor specific antibody
NZ556055A (en) * 2004-12-21 2009-12-24 Viventia Biotech Inc Cancer specific antibody and cell surface proteins
KR101385886B1 (ko) * 2005-02-03 2014-04-24 안티토페 리미티드 인간 항체들과 단백질들

Also Published As

Publication number Publication date
US20080219994A1 (en) 2008-09-11
IL177922A0 (en) 2006-12-31
NZ550339A (en) 2009-11-27
PL1737961T3 (pl) 2013-12-31
US20150018526A1 (en) 2015-01-15
AU2005224942A1 (en) 2005-09-29
DK1737961T3 (da) 2013-08-05
EA200601738A1 (ru) 2007-04-27
PT1737961E (pt) 2013-08-26
EA010803B1 (ru) 2008-12-30
US20050238642A1 (en) 2005-10-27
MXPA06010716A (es) 2007-02-21
JP5025460B2 (ja) 2012-09-12
WO2005090579A1 (en) 2005-09-29
EP1737961A1 (en) 2007-01-03
ES2424643T3 (es) 2013-10-07
HK1102306A1 (en) 2007-11-16
BRPI0508670B1 (pt) 2023-01-24
IL177922A (en) 2011-06-30
CA2560278A1 (en) 2005-09-29
US7339031B2 (en) 2008-03-04
NO338293B1 (no) 2016-08-08
KR20070000494A (ko) 2007-01-02
CA2560278C (en) 2012-11-20
EP1737961A4 (en) 2008-12-17
US20100254964A1 (en) 2010-10-07
US8716234B2 (en) 2014-05-06
JP2008500811A (ja) 2008-01-17
BRPI0508670A (pt) 2007-08-14
US7750136B2 (en) 2010-07-06
AU2005224942B2 (en) 2011-08-11
EP1737961B1 (en) 2013-05-08
KR101165867B1 (ko) 2012-07-13

Similar Documents

Publication Publication Date Title
NO20064134L (no) Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav
Cromm et al. Targeted protein degradation: from chemical biology to drug discovery
DE602005011617D1 (de) Hochaffiner ny-eso-t-zellen-rezeptor
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
MX2011009810A (es) Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor.
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
DK2231860T3 (da) Polypeptid afledt protein A og i stand til at binde PDGF
NO20091235L (no) Antagonistiske humane lysspesifikke monoklonale antistoffer
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
WO2016094873A3 (en) Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
WO2007136685A3 (en) Methods and compositions for inactivation of dihydrofolate reductase
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
PH12020500137A1 (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
NO20063926L (no) N-terminale monopegylerte humane veksthormonkonjugater, fremgangsmater for fremstilling og anvendelse av disse
NO20063026L (no) Antistoffer
WO2005035551A3 (en) Inhibitors of proteins that bind phosphorylated molecules
IN2012DN02981A (no)
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
NO20092360L (no) Nye antiproliferasjonsantistoffer
BRPI0412607A (pt) método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes
BR122018077204B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica